Thursday, February 1, 2018

PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Teams with UniQuest to Develop Novel Cannabinoid Delivery System

  • Global nasal drug delivery technology market expected to reach $64 billion by 2021
  • Development of CBD-infused soluble gel for nasal delivery targets range of diseases
  • Clinical benefits of Sol-gel delivery method include a safer, more reliable delivery platform with higher efficacy
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) and UniQuest Pty Limited, the main commercialization company of the University of Queensland (UQ), Australia, are expecting 2018 to be an exciting, productive year for joint medical research projects. PreveCeutical Medical, headquartered in Vancouver, British Columbia, has entered into a research and option agreement with the University and UniQuest to develop a soluble gel to deliver cannabinoids directly to the brain via the nasal cavity. In a press release discussing the latest research project, UniQuest CEO Dr. Dean Moss said that PreveCeutical’s interest in the University’s intellectual property and expertise to develop soluble gels (Sol-gels) to deliver cannabinoids to the central nervous system (CNS) fit naturally with the company’s research goals (http://nnw.fm/cV6B1).
“Sol-gels potentially provide a safer, more reliable platform to deliver drugs, such as cannabinoids, directly to the CNS, avoiding unwanted rapid metabolism, thus providing clinical benefit from direct nose-to-brain delivery,” Dr. Moss said in the release.
The global nasal drug delivery technology market is projected to reach $64 billion by 2021, expanding at a compound annual growth rate of 6.5 percent, according to a report issued by MarketsandMarkets (http://nnw.fm/usd0S). While the report is segmented based on dosage form, therapeutic application, end user, system, container and region, it also states “intranasal drug delivery is one of the most preferred drug delivery routes among patients as well as healthcare providers.”
PreveCeutical’s proprietary nasal formulations will be designed as a CBD-based nose-to-brain delivery system targeting a range of indications such as pain, inflammation, seizures and neurological disorders. Dr. Harry Parekh, chief research officer for PreveCeutical, will lead the Sol-gel cannabinoid project from his base at the University’s School of Pharmacy.
The Sol-gels begin as a liquid that is sprayed into the nose, which then forms a gel as it is warmed in the nasal cavity. This effectively bypasses the stomach and intestines – eliminating first pass metabolism – and may dramatically improve bioavailability, even compared to nasal sprays and other newer delivery systems.
“This feature can potentially be exploited to deliver drugs through the nasal mucosa,” Dr. Parekh said. “The longer-term goal is to develop Sol-gels as safe, reliable delivery systems for cannabinoid extracts across a range of disease indications.”
Terms of the research program, which has a target start date of March 1, 2018, state that PreveCeutical will own all intellectual property developed under the program and will be granted an option to negotiate an exclusive worldwide license to UniQuest’s background IP.
“Increasing evidence of the clinical benefits associated with cannabinoids and the recent legalization of medical marijuana across a number of jurisdictions were the drivers for the collaboration,” Stephen Van Deventer, PreveCeutical chairman and CEO, added in a news release. “Working with UniQuest and UQ will provide the company with unique opportunities to develop new health and wellness products… Nasal delivery of cannabinoids could potentially provide a safer and more reliable delivery platform with clinical benefits for pain, inflammation, seizures, and mental illness.”
For more information, visit the company’s website at www.PreveCeutical.com
More from NetworkNewsWire
About NetworkNewsWire
NetworkNewsWire (NNW) is a financial news and content distribution company that provides (1) access to a network of wire services via NetworkWire to reach all target markets, industries and demographics in the most effective manner possible, (2) article and editorial syndication to 5,000+ news outlets (3), enhanced press release services to ensure maximum impact, (4) social media distribution via the Investor Brand Network (IBN) to nearly 2 million followers, (5) a full array of corporate communications solutions, and (6) a total news coverage solution with NNW Prime. As a multifaceted organization with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
For more information, please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com

Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)